Detail akcie Simulatns Plus online

Business Summary: Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. Its segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. The Company also provides tech-enabled training and compliance solutions for clinical trial investigators and site staff.
Financial Summary: BRIEF: For the nine months ended 31 May 2024, Simulations Plus Inc revenues increased 17% to $51.3M. Net income decreased 3% to $9.1M. Revenues reflect Software segment increase of 14% to $31.1M, Services segment increase of 21% to $20.2M, Americas segment increase of 20% to $35.8M, Europe segment increase of 26% to $11.5M. Net income was offset by Research and development increase of 12% to $3.8M (expense).